Regeneron's (REGN) Eylea has been approved by FDA
- EYLEA HD® Approved by FDA as First and Only Injectable Anti-VEGF With Dosing Intervals up to 5 Months for Wet Age-Related Macular Degeneration and Diabetic Macular Edema
Context
Regeneron's FDA approval of Eylea represents a significant advancement in the treatment of major eye diseases, which could enhance the product's market position and drive revenue growth. The long dosing interval may differentiate it from competitors, potentially positioning Regeneron favorably in the biotech sector moving forward. This news could also attract investor attention to REGN, reflecting positively on the broader equities market in biotech.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#REGENERON PHARMACEUTICALS INC#REGN.US#FDA#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#NASDAQ 100 INDEX#REGN#US EQUITIES